JPWO2020201138A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020201138A5 JPWO2020201138A5 JP2021557790A JP2021557790A JPWO2020201138A5 JP WO2020201138 A5 JPWO2020201138 A5 JP WO2020201138A5 JP 2021557790 A JP2021557790 A JP 2021557790A JP 2021557790 A JP2021557790 A JP 2021557790A JP WO2020201138 A5 JPWO2020201138 A5 JP WO2020201138A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- erdafitinib
- fgfr2
- platinum
- once daily
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025230741A JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19166429 | 2019-03-29 | ||
| EP19166429.1 | 2019-03-29 | ||
| US201962833395P | 2019-04-12 | 2019-04-12 | |
| US62/833,395 | 2019-04-12 | ||
| PCT/EP2020/058814 WO2020201138A1 (en) | 2019-03-29 | 2020-03-27 | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025230741A Division JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527482A JP2022527482A (ja) | 2022-06-02 |
| JP2022527482A5 JP2022527482A5 (https=) | 2024-07-24 |
| JPWO2020201138A5 true JPWO2020201138A5 (https=) | 2024-07-24 |
Family
ID=69954076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557790A Pending JP2022527482A (ja) | 2019-03-29 | 2020-03-27 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
| JP2025230741A Pending JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025230741A Pending JP2026048748A (ja) | 2019-03-29 | 2025-12-04 | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220175768A1 (https=) |
| EP (2) | EP4548935A3 (https=) |
| JP (2) | JP2022527482A (https=) |
| KR (1) | KR20210143878A (https=) |
| CN (1) | CN113645975A (https=) |
| AU (1) | AU2020253054B2 (https=) |
| BR (1) | BR112021019203A2 (https=) |
| CA (1) | CA3130773A1 (https=) |
| IL (1) | IL286727A (https=) |
| JO (1) | JOP20210260A1 (https=) |
| MA (1) | MA55486A (https=) |
| MX (1) | MX2021011943A (https=) |
| PH (1) | PH12021552352A1 (https=) |
| SG (1) | SG11202109854RA (https=) |
| WO (1) | WO2020201138A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023002980A (es) * | 2020-09-14 | 2023-06-06 | Janssen Pharmaceutica Nv | Terapias de combinación de inhibidores del fgfr. |
| KR20240019293A (ko) * | 2021-06-07 | 2024-02-14 | 알.피.쉐러 테크놀러지즈 엘엘씨 | 습기 감응성 약학 조성물용 보호 코팅 |
| EP4415692A1 (en) | 2021-10-12 | 2024-08-21 | TARIS Biomedical LLC | Erdafitinib formulations and systems for intravesical administration |
| CN119072311A (zh) | 2022-02-18 | 2024-12-03 | 塔里斯生物医药公司 | 用于膀胱内施用的厄达替尼制剂和渗透系统 |
| CN116106240B (zh) * | 2022-12-26 | 2025-11-07 | 华中农业大学 | 一种尿液酪氨酸检测体系、检测方法及检测试剂盒 |
| CN120731076A (zh) | 2023-02-13 | 2025-09-30 | 塔里斯生物医药公司 | 膀胱内施用厄达替尼以用于治疗膀胱癌 |
| JP2026506041A (ja) | 2023-02-17 | 2026-02-20 | タリス バイオメディカル エルエルシー | 膀胱がんの治療における使用のための膀胱内投与のためのエルダフィチニブ |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| MX2007014782A (es) | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| EP4063516A1 (en) | 2014-09-26 | 2022-09-28 | Janssen Pharmaceutica NV | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| AU2018216969B2 (en) * | 2017-02-06 | 2024-04-11 | Janssen Pharmaceutica Nv | Cancer treatment |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2020
- 2020-03-27 SG SG11202109854R patent/SG11202109854RA/en unknown
- 2020-03-27 US US17/598,985 patent/US20220175768A1/en active Pending
- 2020-03-27 EP EP24174999.3A patent/EP4548935A3/en active Pending
- 2020-03-27 AU AU2020253054A patent/AU2020253054B2/en active Active
- 2020-03-27 MA MA055486A patent/MA55486A/fr unknown
- 2020-03-27 CN CN202080026737.4A patent/CN113645975A/zh active Pending
- 2020-03-27 MX MX2021011943A patent/MX2021011943A/es unknown
- 2020-03-27 PH PH1/2021/552352A patent/PH12021552352A1/en unknown
- 2020-03-27 BR BR112021019203A patent/BR112021019203A2/pt unknown
- 2020-03-27 WO PCT/EP2020/058814 patent/WO2020201138A1/en not_active Ceased
- 2020-03-27 KR KR1020217034729A patent/KR20210143878A/ko not_active Ceased
- 2020-03-27 CA CA3130773A patent/CA3130773A1/en active Pending
- 2020-03-27 JP JP2021557790A patent/JP2022527482A/ja active Pending
- 2020-03-27 EP EP20713656.5A patent/EP3946340A1/en active Pending
-
2021
- 2021-09-23 JO JOP/2021/0260A patent/JOP20210260A1/ar unknown
- 2021-09-26 IL IL286727A patent/IL286727A/en unknown
-
2025
- 2025-12-04 JP JP2025230741A patent/JP2026048748A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4337191B1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| CN1191859C (zh) | 用于治疗癌症的泰素帝和重组人源化her2单克隆抗体的组合 | |
| RU2508116C2 (ru) | Способ и композиции для лечения рака | |
| JP2020524698A5 (https=) | ||
| Giralt et al. | Randomized phase 2 trial of a novel clonidine mucoadhesive buccal tablet for the amelioration of oral mucositis in patients treated with concomitant chemoradiation therapy for head and neck cancer | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| WO2022218956A1 (en) | Combination comprising ribociclib and amcenestrant | |
| TW202304424A (zh) | 包含依維莫司和安森司群的組合 | |
| WO2022106711A1 (en) | Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| Patel et al. | Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors | |
| Lüke et al. | Biomodulatory treatment regimen, MEPED, rescues relapsed and refractory classic Hodgkin’s disease | |
| TW200416031A (en) | Therapeutic treatment | |
| JPWO2020201138A5 (https=) | ||
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| JP2021063014A (ja) | 白血病治療薬 | |
| JP2024506385A (ja) | Ｇｄｃ－９５４５及びｇｄｃ－００７７を含む併用療法を使用する乳がんの治療 | |
| JPWO2019196764A5 (https=) | ||
| McCain | Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options | |
| Mantovani et al. | Cancer-related cachexia and oxidative stress: beyond current therapeutic options | |
| Milano et al. | Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck | |
| Saigal et al. | Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma | |
| TW202102211A (zh) | 用於使用６，８－雙－苄硫基－辛酸治療淋巴瘤之治療方法及組成物 | |
| JP2005255643A (ja) | 抗腫瘍効果増強方法および抗腫瘍効果増強剤 | |
| Tran | Adverse effects of the cancer therapy on osteoclast-mediated bone loss in patients with cancers: a challenge |